When Averages Hide Individual Differences in Clinical Trials
The content you've requested is available without charge only to active Sigma Xi members and American Scientist subscribers.
If you are an active member or an individual subscriber, please log in now in order to access this article.
If you are not a member or individual subscriber, you can:
The development and approval of medical therapies today relies on a mid-20th-century invention called the randomized clinical trial. Patients are recruited for an experimental treatment; a random subsample gets a placebo or different approach; any difference in the aggregated outcomes of the groups is attributed to the effects of the treatment. But the risks and benefits of a treatment typically vary substantially from one patient to the next. A small minority of high-risk patients can manifest dramatic results that obscure the fact that the same treatment is barely beneficial or actually harmful to most patients. The authors advocate using risk-stratified analysis to better understand how treatments affect the individual.
Connect With Us:
An early peek at each new issue, with descriptions of feature articles, columns, and more. Every other issue contains links to everything in the latest issue's table of contents.News of book reviews published in American Scientist and around the web, as well as other noteworthy happenings in the world of science books.
To sign up for automatic emails of the American Scientist Update and Scientists' Nightstand issues, create an online profile, then sign up in the My AmSci area.
JSTOR, the online academic archive, contains complete back issues of American Scientist from 1913 (known then as the Sigma Xi Quarterly) through 2005.
The table of contents for each issue is freely available to all users; those with institutional access can read each complete issue.
View the full collection here.
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.